These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 16318869

  • 1. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
    Paola Cellai A, Antonucci E, Alessandrello Liotta A, Fedi S, Marcucci R, Falciani M, Giglioli C, Abbate R, Prisco D.
    Thromb Res; 2006; 118(4):495-500. PubMed ID: 16318869
    [Abstract] [Full Text] [Related]

  • 2. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA.
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
    [Abstract] [Full Text] [Related]

  • 3. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 4. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.
    Saibeni S, Bottasso B, Spina L, Bajetta M, Danese S, Gasbarrini A, de Franchis R, Vecchi M.
    Am J Gastroenterol; 2004 Oct; 99(10):1966-70. PubMed ID: 15447757
    [Abstract] [Full Text] [Related]

  • 5. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
    Cruden NL, Graham C, Harding SA, Ludlam CA, Fox KA, Newby DE.
    Thromb Res; 2006 Oct; 118(2):189-97. PubMed ID: 16055173
    [Abstract] [Full Text] [Related]

  • 6. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y.
    Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
    [Abstract] [Full Text] [Related]

  • 7. [Study of fibrinolysis inhibitors in 117 acute leukemia patients].
    Wang W, Ji CY, Ye JJ, Zhu YY, Guo DM, Ji M.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Mar; 29(3):183-6. PubMed ID: 18788619
    [Abstract] [Full Text] [Related]

  • 8. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level.
    Santamaría A, Martínez-Rubio A, Borrell M, Mateo J, Ortín R, Fontcuberta J.
    Haematologica; 2004 Jul; 89(7):880-1. PubMed ID: 15257950
    [Abstract] [Full Text] [Related]

  • 9. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
    Ricart JM, Ramón LA, Vayá A, España F, Santaolaria ML, Todolí J, Castelló R, Fontcuberta J, Estellés A.
    Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
    [Abstract] [Full Text] [Related]

  • 10. TAFI and PAI-1 levels in human sepsis.
    Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA.
    Thromb Res; 2006 May; 118(2):205-12. PubMed ID: 16009400
    [Abstract] [Full Text] [Related]

  • 11. Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
    Shantsila E, Montoro-García S, Tapp LD, Apostolakis S, Wrigley BJ, Lip GY.
    Thromb Haemost; 2012 Jul; 108(1):32-40. PubMed ID: 22538774
    [Abstract] [Full Text] [Related]

  • 12. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S, Comlekci A, Akinci B, Demir T, Yuksel F, Ozcan MA, Bayraktar F, Yesil S.
    Med Princ Pract; 2009 Jul; 18(4):266-71. PubMed ID: 19494532
    [Abstract] [Full Text] [Related]

  • 13. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 14. The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
    Ozeren M, Karahan SC, Ozgur M, Eminagaoglu S, Unsal M, Baytan S, Bozkaya H.
    Acta Obstet Gynecol Scand; 2005 Oct; 84(10):987-91. PubMed ID: 16167916
    [Abstract] [Full Text] [Related]

  • 15. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P.
    Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
    [Abstract] [Full Text] [Related]

  • 16. PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system.
    Danese S, Papa A.
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):826-8. PubMed ID: 18794594
    [Abstract] [Full Text] [Related]

  • 17. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
    Xu CW, Wang LL, Wu XB, Zhao JJ, Du YM, Jiang CY.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
    [Abstract] [Full Text] [Related]

  • 18. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
    Donmez A, Aksu K, Celik HA, Keser G, Cagirgan S, Omay SB, Inal V, Aydin HH, Tombuloglu M, Doganavsargil E.
    Thromb Res; 2005 Aug; 115(4):287-92. PubMed ID: 15668188
    [Abstract] [Full Text] [Related]

  • 19. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
    Oral B, Mermi B, Dilek M, Alanoğlu G, Sütçü R.
    Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
    [Abstract] [Full Text] [Related]

  • 20. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
    Akinci B, Demir T, Saygili S, Yener S, Alacacioglu I, Saygili F, Bayraktar F, Yesil S.
    Diabetes Res Clin Pract; 2008 Jul; 81(1):93-6. PubMed ID: 18406001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.